全文获取类型
| 收费全文 | 18575篇 |
| 免费 | 1175篇 |
| 国内免费 | 33篇 |
学科分类
| 医药卫生 | 19783篇 |
出版年
| 2023年 | 103篇 |
| 2022年 | 87篇 |
| 2021年 | 343篇 |
| 2020年 | 231篇 |
| 2019年 | 345篇 |
| 2018年 | 505篇 |
| 2017年 | 398篇 |
| 2016年 | 454篇 |
| 2015年 | 535篇 |
| 2014年 | 594篇 |
| 2013年 | 800篇 |
| 2012年 | 1421篇 |
| 2011年 | 1386篇 |
| 2010年 | 699篇 |
| 2009年 | 588篇 |
| 2008年 | 1163篇 |
| 2007年 | 1228篇 |
| 2006年 | 1137篇 |
| 2005年 | 1129篇 |
| 2004年 | 1017篇 |
| 2003年 | 950篇 |
| 2002年 | 848篇 |
| 2001年 | 258篇 |
| 2000年 | 210篇 |
| 1999年 | 210篇 |
| 1998年 | 77篇 |
| 1997年 | 75篇 |
| 1996年 | 52篇 |
| 1995年 | 50篇 |
| 1994年 | 56篇 |
| 1992年 | 84篇 |
| 1991年 | 86篇 |
| 1990年 | 94篇 |
| 1989年 | 112篇 |
| 1988年 | 84篇 |
| 1987年 | 88篇 |
| 1986年 | 77篇 |
| 1985年 | 66篇 |
| 1984年 | 56篇 |
| 1979年 | 69篇 |
| 1978年 | 51篇 |
| 1974年 | 52篇 |
| 1973年 | 46篇 |
| 1936年 | 54篇 |
| 1933年 | 63篇 |
| 1932年 | 66篇 |
| 1931年 | 63篇 |
| 1930年 | 52篇 |
| 1928年 | 52篇 |
| 1927年 | 64篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
2.
3.
4.
5.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献6.
Frédéric Janvier Deborah Delaune Thomas Poyot Eric Valade Audrey Mérens Pierre E. Rollin Vincent Foissaud 《Emerging infectious diseases》2016,22(2):292-294
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly. 相似文献
7.
8.
9.
